Oncternal Therapeutics, Inc.
ONCT · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $0 |
| % Growth | -100% | 40.8% | 91.6% | – |
| Cost of Goods Sold | $0 | $6 | $6 | $7 |
| Gross Profit | $0 | -$5 | -$5 | -$6 |
| % Margin | – | -636.7% | -964.9% | -2,145.8% |
| R&D Expenses | $6 | $7 | $6 | $7 |
| G&A Expenses | $3 | $3 | $3 | $3 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$6 | $0 | $0 |
| Operating Expenses | $9 | $10 | $9 | $10 |
| Operating Income | -$9 | -$9 | -$9 | -$10 |
| % Margin | – | -1,106.5% | -1,542.9% | -3,244.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$8 | -$9 | -$8 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$9 | -$8 | -$9 |
| % Margin | – | -1,068.5% | -1,474.2% | -3,085.5% |
| EPS | -2.86 | -2.89 | -2.83 | -3.11 |
| % Growth | 1% | -2.1% | 9% | – |
| EPS Diluted | -2.86 | -2.89 | -2.83 | -3.11 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $9 | $9 | $10 |
| EBITDA | -$9 | $0 | $0 | -$9 |
| % Margin | – | 0% | 0% | -3,095.3% |